Anti-obesity Drugs Market

Global Anti-obesity Drugs Market is valued at USD 1.68 Billion in 2021 and expected to reach USD 4.49 Billion by 2028 with a CAGR of 15.1% over the forecast period.

Global Anti-obesity Drugs Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2029: Throughout the course of the projected timeframe, factors including rising obesity rates, sedentary living acceptance, an ageing demographic, and the growing prevalence  of chronic ailments  are anticipated to drive market expansion.

Scope-

Obesity is a health disorder wherein  the body absorbs additional fats , potentially harming one's health. Several underlying conditions as well as inherited traits including behavior and genetics may contribute to obesity. Dietary habits, insufficient exercise, the use of medications, as well as other exposures, are examples of behaviors. Weight-reduction or weight-controlling pharmaceuticals include anti-obesity drugs and weight-loss drugs. These drugs affect either hunger or calorie intake, which affects one of the body's basic weight-regulating functions.

Dieting and exercising continue to be the major therapeutic approaches for overweight and obese people. Although the efficacy of these anti-obesity medications is restricted to maintaining a similar weight instead of providing an antidote, essential therapies like limiting the consumption of unhealthy foods and incorporating fitness into daily routines exist. In addition to a calorie-dense meal and absence of exercise, genes and family background also play a significant impact in the emergence of obesity. The use of certain medications contributes to being overweight.

COVID-19 Outbreak Impact-

The abrupt emergence of the COVID-19 virus has increased the need for anti-obesity medications, due to the quick weight gain experienced by persons while sitting at home or working from home. Moreover, future product releases, the availability of important pipeline possibilities at well-known businesses, and a persistent rise in the incidence of obesity are all projected to contribute to the market's significant growth potential after COVID-19.

Key Players-

The  prominent players defining the competitive terrain of this industry vertical are -

• Pfizer Inc.
• VIVUS Inc.
• Bayer AG
• Novo Nordisk
• F Hoffmann-La Roche
• Arena Pharmaceuticals
• Glaxosmithkline
• Takeda Pharmaceutical Company
• Eisai Co. Ltd.
• Nalpropion Pharmaceuticals Inc.

Market Segmentation

By Drug Class

• Pancreatic Lipase Inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors
• Combination Drugs

By Action

• Peripherally Action
• Centrally Action
• Combine Action

By Product

• OTC Drugs
• Prescription Drugs

By Medication

• Monotherapies
• Polytherapies

By Distribution Channel

• Online Pharmacy
• Retail Pharmacy

By Region:

• North America

  • U.S
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers-

Increasing incidence of obesity and Rising Number of Government programmes and initiatives are Some of the Major Factors Driving the Market Growth

Across the globe, the incidence of obesity has dramatically grown, although the rate varies greatly by the nation as a result of bad eating habits and tendencies toward sedentary lifestyles. Although there is no connection between a nation's economic standing and its obesity incidence, it has been observed  that richer nations tend to undertake more programs, initiatives, and efforts to educate and increase public consciousness about healthier lifestyles.

According to a March 2022 article from the WHO, there are more than 1 billion obese individuals in the globe, including 340 million adolescents, 650 million adults, and 39 million children. In addition, the WHO predicted that by 2025, 167 million individuals will be less healthy as a result of getting overweight.

Product Launches By Major Players Due To High Obesity Rate, Increasing Cardiovascular Diseases Are Expected To Propel Market Growth

Due to the increase in the world's obesity rate, the major companies in the market are also developing new products and obtaining market acceptance. In order to find and create therapeutic compounds to treat a range of metabolic diseases, including overweight, diabetes, and other associated ailments, Novo Nordisk joined forces with Evotec AG in 2021. It is anticipated that there would be a significant increase in prospects for industry vendors to produce new goods due to the growing demand for long-lasting medications. This aspect is anticipated to ultimately support market expansion.

The growing prevalence of obesity and accompanying chronic disorders is another factor boosting the industry for anti-obesity medications worldwide. Obesity increases the risk of several chronic illnesses, including cardiovascular illness, certain malignancies, type 2 diabetes, coronary cardiovascular illness, and hypertension. It is a critical human health issue. As per NCBI, obesity is a substantial hazard factor for and contributes to elevated illness and death from cancer, cardiovascular disease, diabetes, liver and renal disease, depression, osteoarthritis, and sleep apnea, as well as other chronic disorders.

Restraints:

High costs Associated with Product Advancement and Stringent Government Approvals Are Expected to Hinder Market Growth

The considerations that are anticipated to limit the requirement for the anti-obesity drug industry include the high cost associated with the advancement and production of prescribing anti-obesity medications, the emergence of ayurvedic weight loss goods, the adverse reactions of anti-obesity substances, as well as rising approval of substitute choices like gyms, fitness spas, as well as treatments to decrease obesity. Additionally, it is anticipated that the industry for over-the-counter medicines would see some growth restraints due to the surge in natural and fat-free goods.

Geographical Landscape-

North America is Expected to Capture a Major Share in the Global Anti-obesity Drugs Market

Geographically, the market in North America, is expected to dominate over the projection period. The significant incidence of overweight in this area, which includes high-income nations with significant healthcare spending per person, is credited with the surge. According to a report by the National Library of Medicine released in 2021, the yearly medical care expenses for obese individuals in the U.S. are considerable at USD 2,505, and they rise sharply with each class of overweight, from 68.4% for class 1 through 233.6% for class 3.

Europe Is Anticipated To Grow At A Considerable Pace Over The Forecast Period.

With the growing pervasiveness of obesity in this region , people are becoming more concerned about getting overweight. This in turn has escalated the demand for anti-obesity medication in Europe.

For example, over one in three youngsters (29% of boys as well as 27% of girls) and greater than 59% of people are overweight or obese, based on the WHO European Regional Obesity Report 2022. The European Area has a greater incidence of obesity rates compared to any other WHO region outside of the Americas, and overweight and obese are among the top sources of mortality and impairment there.

News-

U.S. Food and Drug Administration (FDA) Approved Eli Lilly & Company to Fast Track Status For The Research Of Tirzepatide For The Management Overweight related Illnesses

On October 6^th, 2022; The U.S. Food and Drug Administration (FDA) has given Fast Track status for the research of tirzepatide developed by Eli Lilly & Company. This drug is meant  for the management of people with fat or overweight with weight-related illnesses. . To ease the discovery and speed up the evaluation of medications to treat severe disorders and meet an unmet medical necessity, the FDA provides the classification "Fast Track." The goal of the Fast Track classification is to provide patients with potential medications more quickly.

U.S. Food and Drug Administration Approved Qsymia

On June 27^th, 2022; The U.S. Food and Drug Administration authorized Qsymia as an additional indication for the planning of persistent weight in pediatric physicians 12 years old and older who are obese, as determined by a body mass index (BMI) of 95th percentile or higher when standardized for age and sex. Supplementing a low-calorie diet and greater exercise with Qsymia is recommended.

Novo Nordisk Increased Production Capability For Upcoming Obesity Medicine Releases

On November 3^th, 2022; Novo Nordisk stated that it would increase production capability for upcoming obesity medicine releases and will be less concerned with marketing and promotion following the botched market debut of its Wegovy injectable last year. According to the company, after a subcontractor filling Wegovy injectable pens encountered issues at the end of last year, the business underwent a protracted manufacturing reform.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 1.68 Billion
Base year considered	2021
Forecast Period CAGR %:	15.1%
Market Size Expected in 2028:	USD 4.49 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Pfizer Inc., VIVUS Inc., Bayer AG, Novo Nordisk, F Hoffmann-La Roche, Arena Pharmaceuticals, Glaxosmithkline, Takeda Pharmaceutical Company, Eisai Co. Ltd., and Nalpropion Pharmaceuticals Inc., among others
Segments Covered	By Drug Class, By Action, By Product, By Medication, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa